Existing evidence is insufficient to justify metformin or other agents as first-line therapy for type 2 diabetes

Rene Rodriguez-Gutierrez^{1

2}, Victor M Montori³

Affiliations

¹ Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota, USA.
² Division of Endocrinology, University Hospital 'Dr. Jose E. Gonzalez' Autonomous University of Nuevo Leon, Monterrey, Mexico.
³ Knowledge and Evaluation Research Unit and Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota, USA.

Comment

Rene Rodriguez-Gutierrez et al. Evid Based Med. 2016 Dec.

. 2016 Dec;21(6):224.

doi: 10.1136/ebmed-2016-110562. Epub 2016 Oct 18.

Rene Rodriguez-Gutierrez^{1

2}, Victor M Montori³

¹ Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota, USA.
² Division of Endocrinology, University Hospital 'Dr. Jose E. Gonzalez' Autonomous University of Nuevo Leon, Monterrey, Mexico.
³ Knowledge and Evaluation Research Unit and Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota, USA.

No abstract available

Comment on

Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.
Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, Maggo J, Gray V, De Berardis G, Ruospo M, Natale P, Saglimbene V, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque L, Lloyd A, Ahmad N, Liu Y, Tiv S, Wiebe N, Strippoli GF. Palmer SC, et al. JAMA. 2016 Jul 19;316(3):313-24. doi: 10.1001/jama.2016.9400. JAMA. 2016. PMID: 27434443